Eton Pharmaceuticals (ETON) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Pacira BioSciences (PCRX) over the past year, gaining 161.6% versus a gain of 55.4%. Over five years, ETON leads with a +950.9% price change compared with -31.6% for PCRX. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.45 billion), about 1.1 times the size.
On valuation, Pacira BioSciences trades at a lower forward P/E (10.5x vs 21.2x for Eton Pharmaceuticals). Pacira BioSciences converts more of its revenue into profit, with a net margin of 1.0% versus -5.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | PCRX |
|---|---|---|
| Share price | $54.75 | $36.39 |
| Market cap | $1.56B | $1.45B |
| 1-day change | -0.24% | +44.40% |
| YTD return | +223.77% | +40.61% |
| 1-year return | +161.59% | +55.45% |
| 5-year return | +950.86% | -31.60% |
| P/E ratio (TTM) | 136.88 | 103.97 |
| Forward P/E | 21.22 | 10.52 |
| EPS (TTM) | $0.40 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $726.41M |
| Revenue growth (YoY) | +104.94% | +3.63% |
| Net income (latest FY) | $-4.60M | $7.03M |
| Gross margin | 53.46% | 79.39% |
| Operating margin | -1.06% | 2.64% |
| Net margin | -5.75% | 0.97% |
| 52-week high | $66.37 | $36.46 |
| 52-week low | $14.27 | $18.80 |
| Distance from 52-week high | -17.51% | -0.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +29.68% | -17.26% |
| Average volume | 609.36K | 1.03M |
| Shares outstanding | 28.58M | 39.86M |
| Employees | 44 | 825 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed PCRX by 106.1 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (136.9x vs 104.0x trailing P/E).
- Pacira BioSciences is more profitable, keeping 1.0 cents of every revenue dollar as net income versus -5.8 cents for Eton Pharmaceuticals.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +3.63%).
- The two companies sit in different sectors: Eton Pharmaceuticals in Healthcare and Pacira BioSciences in Health Care.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
ETON vs PCRX FAQ
Which is bigger, Eton Pharmaceuticals or Pacira BioSciences?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, ETON or PCRX?
ETON returned +161.59% over the past 12 months, compared with +55.45% for PCRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or PCRX?
PCRX has the lower trailing P/E at 104.0, versus 136.9 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Pacira BioSciences in the same industry?
No. Eton Pharmaceuticals is in the Healthcare sector, while Pacira BioSciences is in Health Care.